NXL (Nexalin Technology) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NXL Nexalin Technology Inc NXL
42 GF Score
Price $5.05
GF Value $1.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Nexalin Technology Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

NXL
42GF Score
Nexalin Technology Inc NXL
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nexalin Technology (NXL) Overvalued in 2026?

Based on GuruFocus' analysis, Nexalin Technology stock appears to be overvalued. The current stock price of $5.05 is trading 395.1% above its estimated GF Value™ of $1.02. GuruFocus considers Nexalin Technology to be Significantly Overvalued.

Key valuation signals for NXL:

  • Cash Payments:
  • GF Value™: $1.02 vs. price of $5.05 (395.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the NXL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nexalin Technology Business Description

Address 1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
42GF Score

Get the complete analysis for NXL

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.05
Price
$1.02
GF Value